Login to Your Account



Synaffix closes series A round for ADC platform

By Cormac Sheridan
Staff Writer

Tuesday, February 18, 2014
Synaffix BV closed a series A round to take forward its antibody-drug conjugation (ADC) technology, which offers a fresh take on the problem of ADC heterogeneity. The company, based in Oss, the Netherlands, has not disclosed the scale of the funding round.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription